Literature DB >> 32471854

Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?

Sytske Anne Bergstra1, Joy A Van Der Pol2, Naghmeh Riyazi3, Yvonne P M Goekoop-Ruiterman3, Pit J S M Kerstens4, Willem Lems5, Tom W J Huizinga2, Cornelia F Allaart2.   

Abstract

OBJECTIVES: The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic ('curved') decline in the chance to achieve the outcome sustained drug-free remission (sDFR) over time, after which achieving sDFR is not possible anymore, or by a more gradual linear decline approaching zero chance to achieve sDFR.
METHODS: Patients with RA (symptom duration <2 years) were included from two randomised trials: BehandelStrategieën (BeSt), n=508 and Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED), n=479. Cox-regression was performed to assess the shape of the association between symptom duration and sDFR (Disease Activity Score<1.6, no disease-modifying anti-rheumatic drugs for ≥1 year) for patients starting slow-acting monotherapy (IMPROVED, BeSt) or fast-acting combination therapy (BeSt). Likelihood ratio tests were used to compare the fit of linear and non-linear models in both databases separately. Predictions from the best fitting models were used to assess whether the absolute risk to achieve sDFR approaches zero with increasing symptom duration.
RESULTS: In BeSt and IMPROVED, 54/226 and 110/421 patients achieved sDFR with fast-acting treatment, and 53/243 (BeSt) with slow-acting treatment. Non-linear models did not fit better than linear models (fast-acting treatment BeSt p=0.743, IMPROVED p=0.337; slow-acting treatment BeSt p=0.609). After slow-acting monotherapy, linear models declined steeper. None of the models approached zero chance to achieve sDFR over time.
CONCLUSIONS: The chance to achieve sDFR decreased gradually over time, and decreased fastest in patients starting slow-acting monotherapy. In both treatment groups, we found no evidence for a WOO within 2 years symptom duration. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Bone mineral density; Corticosteroids; DMARDs (biologic); DMARDs (synthetic); Disease activity; Osteoarthritis; Osteoporosis; Rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32471854      PMCID: PMC7299505          DOI: 10.1136/rmdopen-2020-001242

Source DB:  PubMed          Journal:  RMD Open        ISSN: 2056-5933


  24 in total

1.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study).

Authors:  Kirsten Wevers-de Boer; Karen Visser; Lotte Heimans; H Karel Ronday; Esmeralda Molenaar; J Hans L M Groenendael; André J Peeters; Marie-Louise Westedt; Gerard Collée; Peter B J de Sonnaville; Bernard A M Grillet; Tom W J Huizinga; Cornelia F Allaart
Journal:  Ann Rheum Dis       Date:  2012-03-08       Impact factor: 19.103

3.  Long-term impact of delay in assessment of patients with early arthritis.

Authors:  Michael P M van der Linden; Saskia le Cessie; Karim Raza; Diane van der Woude; Rachel Knevel; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2010-12

4.  Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation.

Authors:  Katherine J Lee; John B Carlin
Journal:  Am J Epidemiol       Date:  2010-01-27       Impact factor: 4.897

5.  Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.

Authors:  J A B van Nies; R Tsonaka; C Gaujoux-Viala; B Fautrel; A H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2015-01-05       Impact factor: 19.103

6.  Development of a disease activity score based on judgment in clinical practice by rheumatologists.

Authors:  D M van der Heijde; M van 't Hof; P L van Riel; L B van de Putte
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

7.  Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice.

Authors:  D De Cock; G Vanderschueren; S Meyfroidt; J Joly; R Westhovens; P Verschueren
Journal:  Clin Rheumatol       Date:  2014-01       Impact factor: 2.980

8.  The Michael Mason prize: early rheumatoid arthritis--the window narrows.

Authors:  Karim Raza
Journal:  Rheumatology (Oxford)       Date:  2009-12-02       Impact factor: 7.580

9.  Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

Authors:  V P K Nell; K P Machold; G Eberl; T A Stamm; M Uffmann; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  2004-04-27       Impact factor: 7.580

10.  Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression.

Authors:  Silvia Bosello; Anna Laura Fedele; Giusy Peluso; Elisa Gremese; Barbara Tolusso; Gianfranco Ferraccioli
Journal:  Ann Rheum Dis       Date:  2011-04-22       Impact factor: 19.103

View more
  2 in total

Review 1.  Pre-RA: Can early diagnosis lead to prevention?

Authors:  Salina Haville; Kevin D Deane
Journal:  Best Pract Res Clin Rheumatol       Date:  2022-01-03       Impact factor: 4.098

2.  Cross-Tissue Transcriptomic Analysis Leveraging Machine Learning Approaches Identifies New Biomarkers for Rheumatoid Arthritis.

Authors:  Dmitry Rychkov; Jessica Neely; Tomiko Oskotsky; Steven Yu; Noah Perlmutter; Joanne Nititham; Alexander Carvidi; Melissa Krueger; Andrew Gross; Lindsey A Criswell; Judith F Ashouri; Marina Sirota
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.